Business Context and Reporting Period
Company: Retractable Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: The Company designs, develops, manufactures, and markets safety syringes and other safety medical products. Primary products include the VanishPoint insulin syringe and the Patient Safe syringe. Manufacturing occurs in Little Elm, Texas, and via a contract manufacturer in China (Double Dove).
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Sales, Net | $15,914,350 | $11,011,078 |
| Gross Profit | $6,275,878 | $3,568,942 |
| Gross Margin | 39.4% | 32.4% |
| Net Loss | $(5,036,574) | $(6,677,005) |
| Loss Applicable to Common Shareholders | $(5,722,008) | $(7,362,439) |
| Loss Per Share (Basic & Diluted) | $(0.24) | $(0.31) |
| Cash and Cash Equivalents (End of Period) | $11,433,099 | $20,975,485 |
| Working Capital | $22,171,440 | $26,065,703 (Est. based on prior year data) |
| Total Debt (Current + Long-term) | $5,072,026 | $7,453,485 (Est. based on prior year data) |
Note: Working capital calculated as Total Current Assets ($32,690,444) minus Total Current Liabilities ($10,519,004).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 44.5% year-over-year for the six-month period, driven by a 62.0% increase in domestic revenues due to higher volumes and prices. International revenues declined 37.0%.
- Profitability Improvement: Net loss decreased by 24.6% compared to the prior year period. Management attributes this to higher revenues and cost-cutting measures implemented in 2009, despite increased operating expenses related to litigation and stock option amortization.
- Cash Flow: Net cash used by operating activities was $4.28 million, a significant improvement from $10.06 million used in the prior year period. However, cash balances decreased by $6.69 million due to inventory buildup and debt repayments.
- Inventory Buildup: Inventories increased 54.5% to $10.67 million, primarily due to a buildup of finished goods in anticipation of flu season demand.
- Debt Reduction: The Company repaid a $2.12 million loan to 1st International Bank in April 2010, reducing total debt obligations.
Guidance, Outlook, and Material Events
- Litigation Settlements (Post-Period): On July 28, 2010, the Company settled a long-standing dispute with Abbott Laboratories and Hospira. The settlement includes an immediate $6 million payment from Hospira and an option agreement valued at up to $8 million in quarterly payments. Abbott waived rights to accrued preferred stock dividends.
- Patent Litigation: A final judgment was entered in May 2010 awarding the Company $5 million plus interest against Becton Dickinson (BD) for patent infringement. A permanent injunction against BD's Integra syringes was ordered but stayed pending appeal.
- Market Access Risks: Management notes continued difficulty accessing hospital markets due to monopolistic practices by competitors. The Company relies on litigation and alternative market strategies to maintain access.
- Cost Cutting: The Company continues to implement cost-saving measures, including workforce reductions and salary cuts, to preserve cash. These measures reduced compensation costs by approximately $809,000 in the first six months of 2010.
- Seasonality: Historically, unit sales increase in the latter part of the year due to flu season demand. The Company does not expect a repeat of the 2009 Swine Flu government contract program in 2010.
Investor Verification Checklist
- Litigation Proceeds: Verify the receipt of the $6 million settlement payment from Hospira and the status of the $5 million BD judgment collection.
- Inventory Valuation: Assess the risk of obsolescence given the 92.4% increase in finished goods inventory and the potential for demand fluctuations post-flu season.
- Supplier Concentration: Confirm the stability of the supply chain with Double Dove (China), which provided 66.0% of finished products in the first half of 2010.
- Preferred Stock Arrears: Review the total dividends in arrears for Series III, IV, and V Class B Preferred Stock, which total over $15 million, impacting common shareholder distributions.
- Market Access: Monitor the outcome of the BD appeal regarding the permanent injunction, as this directly impacts the Company's ability to compete in the hospital market.